Press Release
China Medical System: First Prescriptions for Innovative Drug Lumeblue® Issued in China
SHENZHEN, CHINA – On 6 December, China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that the first prescriptions for the innovative drug Lumeblue® (Methylthioninium Chloride Enteric-coated Sustained-release Tablets) (the “Product”) have been issued in China, which marks that the first oral methylthioninium chloride enteric-coated sustained-release tablets in China has officially entered clinical application. The Product is indicated for enhancing visualization of colorectal lesions in adult patients undergoing screening or surveillance colonoscopies.
Lumeblue® is an oral diagnostic drug that uses patented multi-matrix (MMXTM) technology to deliver active substances directly to the colon and release them locally in a controlled manner. As an enhancer dye, the Product increases the contrast between colorectal lesions and healthy mucosa. The results of the Phase III clinical trial in China show that the Product can significantly improve the detection rate of non-polypoid colorectal lesions (the primary endpoint of the study), leading to an improved detection rate of dangerous lesions such as non-polypoid adenomas (the secondary endpoint)[1]. In addition, the Product can be taken during the bowel preparation step, ensuring that colorectal staining is completed by the time colonoscopy is conducted. This not only enhances the detection rate of colorectal lesions but also potentially simplifies the colonoscopy procedure, making the examination more efficient and improving the screening benefits.
According to the diagnosis and treatment data of the Digestive Endoscopy Branch of the Chinese Medical Association, approximately a total of 28 million gastroenteroscopies were completed nationwide in 2012, including 5.83 million colonoscopies. In 2019, approximately 38.73 million gastroenteroscopies were completed nationwide, an increase of 34.62% compared with 2012[2]. The Expert consensus on the early diagnosis and treatment of colorectal cancer in China (2023 edition) recommends colorectal cancer screening for individuals aged 40 to 74[3]. Based on the China Statistical Yearbook (2023), the total population of this age group in China is 643.36 million[4]. With the popularization of early colorectal cancer screening in China, the number of colonoscopies performed is expected to have significant growth potential in the future. Early diagnosis and removal of lesions are crucial for prevention. Lumeblue® provides an innovative solution for colorectal disease screening and management in response to this growing demand.
The Product has been approved by the European Medicines Agency (EMA) to be commercialized in the European Union under the trade name Lumeblue® in August 2020. The Group obtained an exclusive license for the Product from Cosmo Technologies Ltd., a fully-owned subsidiary of Cosmo Pharmaceuticals NV, on 3 December 2020. Following its approval in China in June 2024, CMS worked collaboratively across its business segments to ensure the rapid importation of the first batch of products. The Group has also actively leveraged its existing gastroenterology portfolio and resources to orderly advance the commercialization and academic promotion of Lumeblue®, facilitating its successful prescriptions launch in China.
With this milestone, CMS’s five innovative drugs have been successfully approved in China and fully entered clinical application. This achievement demonstrates the Group’s ongoing capability of innovation transformation, while reflecting CMS’s commitment to focusing on medical value and fulfilling its corporate social responsibility. Looking ahead, CMS will continue to be patients-centered, efficiently advancing the clinical development and commercialization of innovative products. The Group is dedicated to improving the accessibility and affordability of innovative drugs, benefiting a broader patient population.
About CMS
CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.
CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.
CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development of its advantageous specialty fields and expand business boundaries. While strengthening the competitiveness of the cardio-cerebrovascular/gastroenterology business, CMS independently operates its dermatology and medical aesthetics business, and ophthalmology business, aiming to gain leading positions in specialty therapeutic fields, whilst enhancing the scale and efficiency. At the same time, CMS has expanded its business territory to the Southeast Asian market, striving to become a “bridgehead” for global pharmaceutical companies to enter the Southeast Asian market, further escorting the sustainable and healthy development of the Group.
References:
CMS Disclaimer and Forward-Looking Statements
This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.
This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.
Media Contact
Brand: China Medical System Holdings Ltd.
Contact: CMS Investor Relations
Email: ir@cms.net.cn
Website: https://web.cms.net.cn/en/home/
Source: China Medical System Holdings Ltd.
- The results of the Product’s Phase III clinical trial in China were published and are available at: https://web.cms.net.cn/en/2022/12/positive-results-for-china-phase-iii-c…
- Data from the Digestive Endoscopy Branch of the Chinese Medical Association
- Early Diagnosis and Treatment Group of the Chinese Society of Oncology. “Expert Consensus on Early Diagnosis and Treatment of Colorectal Cancer in China (2023 Edition).” Chinese Medical Journal, 2023, 103(48): 3896-3908. DOI: 10.3760/cma.j.cn112137-20230804-00164
- National Bureau of Statistics. (2023). China Statistical Yearbook 2023. Retrieved from https://www.stats.gov.cn/sj/ndsj/2023/indexch.htm
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Founded in 2019, Air Tolentino is a locally owned and operated HVAC company providing reliable heating, ventilation, and air conditioning services across Northeast Florida. With a mission rooted in integrity and customer care, Air Tolentino continues to grow without losing the personalized touch that sets them apart.
Orange Park, FL, United States, 17th Jun 2025 – After five years of quietly becoming one of Northeast Florida’s most trusted HVAC service providers, Air Tolentino is stepping into the spotlight—ready to expand and serve even more homes and businesses across Orange Park and beyond.
Led by owner Mark Tolentino and HVAC veteran Kris Latuch, Air Tolentino has built its reputation solely through word-of-mouth referrals, offering fast, honest, and family-style service with no gimmicks or sales pressure. Now, with plans to launch subscription maintenance services, open a dedicated Orange Park location, and potentially expand into commercial HVAC, the team is turning up the heat.
“We’ve always focused on treating people like family,” said Kris Latuch, who’s served alongside Mark for the past three summers. “Now we’re ready to bring that same energy to more customers, without sacrificing the quality that’s gotten us this far.”
Air Tolentino serves:
- Orange Park
- Jacksonville
- Fleming Island
- St. Augustine
- Ponte Vedra Beach
- and surrounding areas
Whether it’s emergency AC repair, routine maintenance, or a complete system overhaul, Air Tolentino is committed to keeping Florida cool—one home at a time.
Media Inquiries & Interviews:
Mark Tolentino
(904) 314-4564
https://airtolentino.com/
6625 Argyle Forest Blvd #4
Jacksonville, FL 32244
Media Contact
Organization: Air Tolentino
Contact Person: Kris Latuch
Website: https://airtolentino.com/
Email: Send Email
Contact Number: +19043144564
Address:6625 Argyle Forest Blvd #4
City: Orange Park
State: FL
Country:United States
Release id:29249
The post Orange Parks Best-Kept Secret in AC Repair Is Ready to Make Noise Meet Air Tolentino appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Pakistan, 17th Jun 2025 – In the fast-paced world of NFTs, timing and presentation are everything. From art-based collections to utility-driven tokens, NFT creators face the challenge of standing out in a crowded digital space. A press release can play a crucial role in building excitement and legitimacy around a launch.
This service is built for NFT and Web3 creators who want to announce their collections with clarity and professionalism. Whether you’re revealing minting dates, artist collaborations, or introducing staking mechanics — a strong PR can significantly increase your reach.
What You Can Expect:
Targeted Writing: Releases are tailored to resonate with NFT collectors, crypto users, and mainstream audiences.
Structured Messaging: Content includes project overview, utility highlights, team info, and roadmap elements.
Media-Ready Formatting: Designed to be shared on NFT blogs, marketplaces, and crypto news platforms.
A well-written press release ensures your audience — whether they’re potential buyers or community members — understands the value and vision behind your drop. Let your launch story be heard loud and clear.
Check out the gig now: NFT PR Service on Fiverr
Media Contact
Organization: Khizra Amer PR Services
Contact Person: Khizra
Website: https://www.fiverr.com/s/421E26B
Email: Send Email
Country:Pakistan
Release id:29132
View source version on King Newswire:
Announce Your NFT Drop with Confidence Using Professional Press Releases
This content is provided by a third-party source. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release.
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Press Release
Drs Osman Ahmed and Mikin Patel Launch Joint and Vascular Institute to Deliver Patient-Centered Minimally Invasive Care in Chicago
The Joint and Vascular Institute, a leading provider of minimally invasive procedures for pain relief and vascular conditions, is proud to debut its founders and clinical leaders: Dr. Osman Ahmed and Dr. Mikin Patel. As visionaries behind the Institute, Drs. Ahmed and Patel established the practice to revolutionize outpatient care through innovative, patient-first interventional radiology solutions. Conceived from their shared mission to make world-class, image-guided therapies more accessible to the patient community, the Joint and Vascular Institute now serves greater Chicago area with a unique blend of compassion, precision, and speed-to-recovery that is redefining what it means to receive modern vascular and joint care.
Libertyville, IL, United States, 17th Jun 2025 – The Joint and Vascular Institute, a leading provider of minimally invasive procedures for pain relief and vascular conditions, is proud to debut its founders and clinical leaders: Dr. Osman Ahmed and Dr. Mikin Patel.
As the visionaries behind the Institute, Drs. Ahmed and Patel established the practice to revolutionize outpatient care through innovative, patient-first interventional radiology solutions.
Conceived from their shared mission to make world-class, image-guided therapies more accessible to the patient community, the Joint and Vascular Institute now serves greater Chicago area with a unique blend of compassion, precision, and speed-to-recovery that is redefining what it means to receive modern vascular and joint care.
Co-Founder Dr. Osman Ahmed, MD
Dr. Ahmed brings unmatched clinical knowledge and a patient-first philosophy. He specializes in treating osteoarthritis and other musculoskeletal pain conditions, BPH (enlarged prostate), uterine fibroids, and internal hemorrhoids using advanced embolization techniques.
He is also a leading expert and pioneer in the United States for the advancement of genicular artery embolization, a minimally invasive treatment for symptomatic knee osteoarthritis.
Dr. Ahmed is a board-certified vascular and interventional radiologist and a Professor of Radiology. He graduated from the University of Illinois College of Medicine, completed his internship at NorthShore University HealthSystem, his residency at the University of Chicago Medicine, and his fellowship at the Stanford University School of Medicine.
“One of the greatest parts of my job is offering patients options they haven’t heard of before—real alternatives to surgery,” Dr. Ahmed explains. “Seeing them recover quicker and return home sooner makes everything worthwhile.”
Dr. Ahmed’s contributions extend well beyond patient care. A noted researcher and international speaker, his work has been featured in top medical journals including Radiology, Chest, Journal of Vascular and Interventional Radiology, and Journal of Surgical Oncology. He is a passionate advocate for expanding access to innovative treatments and educating the next generation of physicians
Co-Founder Dr. Mikin V. Patel, MD
Dr. Patel is focused on offering patients alternatives to traditional surgery that are not only effective but also far less disruptive to daily life. His approachable style, combined with deep technical expertise, empowers patients to take an active role in their care and recovery.
“For years, we have been pioneering and teaching other doctors how to perform innovative, minimally invasive treatments to help patients. Now, we have figured out how to bring these same treatments to the patients without having to deal with the headache of a big hospital. Getting high level care doesn’t have to be complicated. We’re about improving quality of life in a way that’s safe, effective, and convenient.”
Dr. Patel is a board-certified expert in Interventional Radiology and Diagnostic Radiology. He earned his medical degree from the University of Illinois College of Medicine and completed his internship at NorthShore University HealthSystem. He then trained at the University of Chicago Pritzker School of Medicine and completed a prestigious fellowship at Northwestern Memorial Hospital.
A Different Kind of Healthcare Experience
The Joint and Vascular Institute reimagines the outpatient healthcare experience. The mission: deliver highly specialized interventional procedures in a welcoming environment where patients receive direct access to physician expertise without the cost, complexity, or recovery of major surgery.
Located in Libertyville, IL, the Institute provides minimally invasive, image-guided solutions for:
- Hemorrhoid Artery Embolization
- Genicular Artery Embolization (knee pain relief)
- Shoulder Artery Embolization (frozen shoulder treatment)
- Uterine Fibroid Embolization (UFE)
- Prostate Artery Embolization (PAE for BPH)
- Plantar Fasciitis Embolization
- Hip Embolization
- Thyroid Embolization
These procedures are performed through a small incision, often in under an hour, using imaging technology that guides precision tools to the treatment site. The result is reduced pain, fewer risks, and faster recovery—all without general anesthesia or a hospital stay.
“We’re not just treating symptoms—we’re partnering with our patients from the first visit onward,” says Dr. Ahmed. “Every procedure is a coordinated effort between our physicians, nurses, technologists, and support team to deliver the best possible outcome.”
Empowering the Community Through Education and Access
One of the foundational goals Dr. Ahmed and Dr. Patel had in creating the Joint and Vascular Institute was to increase access to world-class interventional care. Their practice not only removes many of the financial and recovery-related barriers associated with surgery but also emphasizes patient education and engagement.
“We’re helping people regain their quality of life—whether it’s being able to go up stairs without pain, sleep comfortably, or lift their grandkids. These may seem like small wins, but for our patients, they’re everything,” says Dr. Patel.
Looking Ahead: Vision and Values
As founders, Drs. Ahmed and Patel are committed to continual growth, innovation, and advocacy. The Joint and Vascular Institute is already a regional leader in outpatient interventional care, and plans are in motion to expand offerings and reach even more patients
“We’re here to change the way people think about getting treated,” says Dr. Ahmed. “Minimally invasive care isn’t just an option—it’s often the best one. We want to make sure every patient knows that.”
Visit the Joint and Vascular Institute
Patients and providers can learn more about services, scheduling, and conditions treated by visiting https://jointvascular.com or calling (847) 584-3959.
Media Contact
Organization: Joint & Vascular Institute
Contact Person: Dr. Osman Ahmed, MD
Website: https://jointvascular.com
Email: Send Email
Contact Number: +18475843959
Address:950 Technology Way
Address 2: Suite 250
City: Libertyville
State: IL
Country:United States
Release id:29247
The post Drs Osman Ahmed and Mikin Patel Launch Joint and Vascular Institute to Deliver Patient-Centered Minimally Invasive Care in Chicago appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Orange Parks Best-Kept Secret in AC Repair Is Ready to Make Noise Meet Air Tolentino
Drs Osman Ahmed and Mikin Patel Launch Joint and Vascular Institute to Deliver Patient-Centered Minimally Invasive Care in Chicago
Announce Your NFT Drop with Confidence Using Professional Press Releases
Bay Smokes Maintains Quality Amid Legislative Changes in the Hemp Industry
Benzinga Money Article Discusses How to Become Part of the 12% of Retirees Who Have Achieved the Recommended $550,000 Minimum Retirement Savings Threshold
Apu Apustaja Conquers New York with Lively Street Ads, Including Times Square Billboard
-
Press Release3 days ago
Dallas Agency Breaks Industry Norms with Risk-Free Reputation Management Trial for Small Businesses
-
Press Release1 week ago
InnoTek Computer Consulting Empowers Businesses in Bethlehem PA with Reliable IT Support and Strategic Technology Services
-
Press Release4 days ago
Querv Exchange Upgrades Web Platform with Multilingual and Intelligent Navigation
-
Press Release7 days ago
Dr Yahia Ananes Metabolic Protocol Offers New Integrative Strategy for Chronic Illness and Cancer Support
-
Press Release7 days ago
Driven by RWA and AI, NPC leads the new era of crypto finance
-
Press Release2 days ago
Coinsult Sets the Standard in Smart Contract Audits With Proven Track Record and Introduces New Dashboard
-
Press Release1 week ago
Bitnile.com, a Subsidiary of Hyperscale Data, Now Accepts Nile Coin for Social Casino Gaming
-
Press Release1 week ago
BingX and Chelsea FC Unveil 25/26 Training Kit with “Trained on Greatness” Campaign